Home » Newsletters » BioWorld Science

BioWorld Science

April 4, 2005

View Archived Issues

Methylene blue increases brain oxygen consumption and facilitates memory retention in rats

Neuroprotective effects of S-34176, a free radical scavenger

Chronic gamma-secretase blockade safe and beneficial in experimental AD / News in Context

TheraQuest pain drug candidates investigated in preclinical, clinical studies

(-)-BPAP HCl neuroprotective in organotypic slice cultures

A phase III trial finds no efficacy for edifoligide in the prevention of CABG failure

NuvaRing reported as effective as an oral combination of contraceptives

Clinical evidence supports the use of laquinimod in multiple sclerosis

Gaboxadol shows promise in the treatment of insomnia in elderly subjects

Studies reveal therapeutic value of pregabalin in treating neuropathic pain

ALGRX-4975 reduces pain in osteoarthritis, bunionectomy

Orphan medicinal product status for TGN-1412 in Europe

Maruho and Toray Industries to jointly develop TRK-820 in Japan

Topical anesthesia with ALGRX-3268 tested in children undergoing venipuncture

Keppra effective in adjunctive treatment of myoclonic seizures

Sativex improves pain and symptoms in multiple sclerosis

Serono licenses Syntonix' technologies to develop inhalable interferon-beta:Fc

New patents disclose therapeutic agents for cancer

Novel immunomodulatory agents disclosed by CNRS and INSERM

Recent patents describe new antiinfective compounds

Past Tysabri patient had PML

ImmunoGen submits IND for huC242-DM4

Aeras and Statens Serum Institut team up on TB vaccine development

Enrollment completed in U.S. Fluviral study

ExCel study to investigate ability of exemestane to prevent breast cancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...